| Identification | Back Directory | [Name]
Phenol, 5-ethoxy-2-(3,4,9,10-tetrahydro-8,8-dimethyl-2H,8H-benzo[1,2-b:3,4-b']dipyran-3-yl)- | [CAS]
1800188-47-9 | [Synonyms]
HSG4112
Vutiglabridin
Phenol, 5-ethoxy-2-(3,4,9,10-tetrahydro-8,8-dimethyl-2H,8H-benzo[1,2-b:3,4-b']dipyran-3-yl)- | [Molecular Formula]
C22H26O4 | [MOL File]
1800188-47-9.mol | [Molecular Weight]
354.44 |
| Chemical Properties | Back Directory | [Boiling point ]
463.0±45.0 °C(Predicted) | [density ]
1.155±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
9.55±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Vutiglabridin (HSG4112), a racemic compound, is a potent anti-obesity agent[1]. Vutiglabridin, an optimized structural analog of Glabridin, markedly supersedes Glabridin in weight reduction efficacy and chemical stability[1]. | [in vivo]
Vutiglabridin (HSG4112) fully reverses adiposity in HFD-induced obese mice in a dose-dependent manner. Vutiglabridin (orally administered with 10, 30, or 100?mg/kg dose for 6 weeks) dose-dependently reduces body weight and normalizes obesity-related parameters in high-fat diet (HFD)-induced obese mice[2]. | Animal Model: | HFD-induced obese male C57BL/6J mice[2] | | Dosage: | 10, 30, and 100?mg/kg | | Administration: | Orally administered for 6 weeks | | Result: | Led to significant dose-dependent body weight reduction by 4.0?g (8.3%), 10?g (21%), and 19?g (40%), respectively, compared to the 48.1?g body weight of HFD-induced obese mice administered with only the vehicle at 10, 30, and 100?mg/kg. |
| [References]
[1] In Yong Bae, et al. Species Differences in Stereoselective Pharmacokinetics of HSG4112, A New Anti-Obesity Agent. Pharmaceutics. 2020 Feb 3;12(2):127. DOI:10.3390/pharmaceutics12020127
[2] Leo Sungwong Choi, et al. Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity. Int J Obes (Lond). 2021 Jan;45(1):130-142. DOI:10.1038/s41366-020-00686-1 |
|
|